Many scientists and physicians believe in the healing power of heat, but to date, there have been no major commercial successes in hyperthermia. Hyperthermia companies suffer from the field's checkered past: a wave of commercial hyperthermia flameouts in the 1980's means that many investors won't give hyperthermia companies a second glance. First Circle Medical's challenge is to win over skeptical investors and clinicians as it pursues a new device market for hepatitis C. There it aims to offer a side effect free alternative to drugs for a deadly and prevalent disease with few therapeutic options, or, at the very least, a procedure that will potentially boost the efficacy of drugs. But as the first and only player in a new field, and in light of the prejudice against hyperthermia devices that many share, First Circle has to create a base of rigorous scientific data from scratch; indeed, it has to bear the burden of doing everything right.
by Mary Stuart
Every century has had its believers in the therapeutic power of heat. "Give me the power to create fever in...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.
